Cardiovascular diseases are a leading cause of mortality in the United States. The increasing number of cancer patients experiencing cardiovascular side effects from chemotherapeutic drugs is a cause for concern. Trastuzumab is a highly effective targeted therapy for HER2-positive cancers but its use is limited globally due to its cardiotoxic effects. The most severe adverse effect is cardiomyopathy, which is characterized by contractile dysfunction and reduced left ventricular systolic function. The electrophysiological side effects of trastuzumab are still not fully understood. Due to these life-threatening side effects, trastuzumab is routinely discontinued. This review aims to provide a comprehensive overview of trastuzumab-induced cardiomyopathy, including the mechanisms by which trastuzumab exerts its cardiotoxic effects, the clinical manifestations, diagnostic strategies, and potential interventions to protect the heart. By shedding light on the various aspects of this condition, we hope to emphasize the importance of early detection and effective management, as well as the urgent need for further research to optimize the balance between successful cancer treatment and cardiovascular well-being. Cardiologists, oncologists, and researchers are at the forefront of this critical intersection between oncology and cardiology, working collaboratively to enhance patient outcomes in the era of trastuzumab therapy.

Cardiovascular diseases are one of the most common causes of death in the United States of America and the sudden rise of patients having cancer are suffering from cardiovascular side effects of Chemotherapeutics drugs. Trastuzumab is a potent targeted agent for HER2-positive cancers though despite its excellent efficacy, the cardiotoxic effects of Trastuzumab restrict its usage globally. The most severe adverse effect is cardiotoxicity presents as contractile dysfunction that is reduction in left ventricular systolic function but the electrophysiological side effects are still not known. Due to these severe life-threatening side effects, it routinely results in the cessation of Trastuzumab. This review aims to provide a comprehensive overview of Trastuzumab-induced cardiomyopathy, offering insights into the mechanisms through which Trastuzumab exerts its cardiotoxic effects, clinical manifestations, diagnostic strategies, and potential cardioprotective interventions. By shedding light on the multifaceted aspects of this condition, we hope to emphasize the importance of early detection and effective management, while highlighting the urgent need for continued research to optimize the balance between oncological success and cardiovascular well-being. Cardiologists, oncologists, and researchers stand at the forefront of this critical intersection between oncology and cardiology, collectively striving to improve patient outcomes in the era of Trastuzumab therapy.

Aspirin is used in patients with coronary artery disease essential in both acute and chronic phases of treatment, especially post-catheterization and post-coronary artery stent placement. Some patients have sensitivity to aspirin. Hypersensitivity reaction symptoms include itchy and watery eyes, itchy rash, worsening asthma, wheezing to fatal angioedema, and anaphylaxis. In such cases, clopidogrel can be used instead of aspirin if it is necessary to avoid the use of aspirin. Alternatively, we can try desensitization to aspirin. In aspirin desensitization, incremental doses of aspirin are provided at fixed time intervals. It usually lasts between one and three days. These protocols are often impractical in emergent conditions, especially in conditions where percutaneous coronary intervention (PCI) reveals coronary artery stenosis requiring stent placement. Post-stent placement long-term treatment with aspirin is needed. This has led to limited application in clinical practice despite the potential benefits. We present a case of a patient who presented to us with complaints of shortness of breath and intermittent chest pain. A thorough evaluation was conducted, including cardiac catheterization, which revealed a 70% blockage in the right coronary artery (RCA) and a 65% blockage in the left anterior descending (LAD) artery, necessitating stent placement. The patient reported a severe allergy to aspirin, requiring aspirin desensitization. Rapid aspirin desensitization was successfully performed in the ICU, taking two hours and 15 minutes. The patient underwent PCI and stent placement in the RCA the following day. She is currently on dual antiplatelet therapy with aspirin and clopidogrel and has scheduled follow-ups with both a cardiologist and an allergist.